Skip to main content

Table 1 Clinical characteristics of the included patients

From: New therapeutic targeting of Alzheimer’s disease with the potential use of proline-rich polypeptide complex to modulate an innate immune response - preliminary study

Variable

Min

Q1

Median

Q3

Max

 Age

43

65.75

68.5

74

79

 BMI

18.5

20.75

22.5

23

25

 CRP before

0.30

1.00

1.16

2.15

12.90

 CRP after

0.31

1.00

1.33

1.98

14.92

 CRP before-after

−11.90

−0.18

0.01

0.48

13.69

 MMSE

12

14

19

22

23

 MoCA 7.2

3

10.75

14

16.25

23

DSM V classification

     Mild

Moderate

Serious

         n

%

n

%

n

%

         5

25

7

35

8

40

Gender

n

%

Age*

BMI*

MMSE*

Men

7

35

69

22

18

Women

13

65

68

23

19

  1. Q1, Q3—1st and 3rd quartile; *median